Targeting Glycolysis in Leukemia: A Novel Inhibitor 3-BrOP in Combination With Rapamycin

Leukemia Research - United Kingdom
doi 10.1016/j.leukres.2010.12.028
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

A Novel Combination Therapy Approach for the Treatment of Acute Myeloid Leukemia: The Multi-Kinase Inhibitor Sorafenib and the HDM2 Inhibitor Nutlin-3

Haematologica
Hematology
2012English

Enhanced Antitumor Activity of 3-Bromopyruvate in Combination With Rapamycin in Vivo and in Vitro

Cancer Prevention Research
MedicineCancer ResearchOncology
2015English

Targeting 14-3-3 Sensitizes Native and Mutant BCR-ABL to Inhibition With U0126, Rapamycin and BCL-2 Inhibitor GX15-070

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2007English

Pharmacokinetics/Pharmacodynamics of Vaborbactam, a Novel Beta-Lactamase Inhibitor, in Combination With Meropenem

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
2018English

Combination Treatment of an IDH1 Inhibitor With Chemotherapy in IDH1 Mutant Acute Myeloid Leukemia

Annals of Hematology
MedicineHematology
2020English

A Novel Treatment Strategy Targeting Aurora Kinases in Acute Myelogenous Leukemia

Molecular Cancer Therapeutics
Cancer ResearchOncology
2007English

785 Benserazide Is a Novel Inhibitor Targeting PKM2 in Melanoma Treatment

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2019English

Targeting Glycolysis in the Malaria parasitePlasmodium Falciparum

FEBS Journal
BiochemistryCell BiologyMolecular Biology
2016English

The mTOR Inhibitor Everolimus in Combination With Azacitidine in Patients With Relapsed/Refractory Acute Myeloid Leukemia: A Phase Ib/Ii Study

Oncotarget
Oncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy